ObsEva S.A. OBSV
Day range unavailable
52-week range unavailable
- Market cap
- 11.00M
- Revenue (ttm)
- 3.71M
- Shares out
- 108.02M
- Forward P/E
- -0.78
- Beta
- 0.67
- Analysts
- Hold
- Price target
- 12.00 (+11687.8%)
- Earnings date
- Mar 23, 2023
2Y -2.4960 (-96.74%)
Key statistics
- Enterprise value
- 8.92M
- PEG ratio
- 0.00
- Price / sales
- 2.96
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -85.20%
- Free cash flow
- -22.65M
- Total cash
- 9.68M
- Total debt
- 9.27M
- Return on equity
- -373.98%
- Short % of float
- 0.78%
- 50-day average
- 0.135727
- 200-day average
- 0.26982
Analyst view
Consensus: hold
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 23, 2023
Expected Mar 23, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 23, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Dec 1, 2022 | Sep 1, 2022 | -0.14 | — | — | — |
| Aug 17, 2022 | Jun 1, 2022 | -0.22 | — | — | — |
| May 17, 2022 | Mar 1, 2022 | -0.25 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -0.22 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.22 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 30, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 3, 2022 | Cantor Fitzgerald | init | — | Overweight |
| Apr 26, 2022 | Canaccord Genuity | init | — | Buy |
| Mar 28, 2022 | Aegis Capital | init | — | Buy |
| Mar 28, 2022 | HC Wainwright & Co. | main | — | Buy |
| Nov 29, 2021 | HC Wainwright & Co. | main | — | Buy |
About ObsEva S.A.
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- obseva.com
News
Reviewing ObsEva (NASDAQ:OBSV) & ProMetic Life Sciences (OTCMKTS:PFSCF) 
Contrasting ObsEva (NASDAQ:OBSV) & Avenue Therapeutics (NASDAQ:ATXI) 
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin 
ObsEva Announces Update on Board of Directors 
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023 
Geneva Court Grants Temporary Moratorium to ObsEva 
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals 
Organon Returns Ebopiprant to XOMA 
ObsEva Files half Year 2023 Financial Statements 
ObsEva Recovers Full Worldwide Rights on Nolasiban
Your note
Sign in to keep a note on OBSV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LOUMAYE ERNEST | Director | Purchase | Feb 27, 2023 | 6,000,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 4.37% | 4,749,623 | 483.51K | Dec 30, 2022 |
| NEA Management Company, LLC | 4.22% | 4,586,563 | 466.91K | Dec 30, 2022 |
| Credit Suisse Ag/ | 1.61% | 1,750,573 | 178.21K | Dec 30, 2022 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0.62% | 668,485 | 68.05K | Dec 30, 2022 |
| Pictet Asset Management SA | 0.33% | 363,772 | 37.03K | Dec 30, 2022 |
| Cutter & Co. Brokerage, Inc. | 0.19% | 201,200 | 20.48K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.08% | 82,227 | 8.37K | Nov 29, 2022 |